Seres Therapeutics. has filed a patent for therapeutic compositions containing Ecobiotic™ populations. These compositions aim to prevent, treat, and reduce symptoms associated with dysbiosis in mammals, including humans. The patent claim specifies the composition of isolated bacteria species that are at least 97% identical to reference bacteria and have the ability to inhibit the growth of Clostridium difficile. GlobalData’s report on Seres Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Seres Therapeutics, Microbiota restoration therapy was a key innovation area identified from patents. Seres Therapeutics's grant share as of September 2023 was 23%. Grant share is based on the ratio of number of grants to total number of patents.
Therapeutic compositions for dysbiosis treatment using ecobiotic™ populations
A recently filed patent (Publication Number: US20230226126A1) describes a composition comprising two species of isolated bacteria that are capable of inhibiting the growth of Clostridium difficile (C. difficile). The first and second species of bacteria are not identical and independently contain a 16S rDNA sequence that is at least 97% identical to a reference bacterium listed in Table 3. The composition is formulated to populate the gastrointestinal tract of a subject and may also include an enteric coating. The bacteria in the composition can be in the form of spores and may be lyophilized for stability.
The patent also claims methods of using the composition for treating or preventing recurrence of Clostridium difficile infection in a subject, as well as treating dysbiosis. The composition can be administered to the subject, either alone or in combination with additional agents such as antibiotics. The patent also describes a single dose unit comprising the two species of bacteria, which can inhibit C. difficile growth and/or populate the gastrointestinal tract of a subject.
Furthermore, the patent includes a kit containing the composition and a pharmaceutical formulation comprising the composition. The pharmaceutical formulation may also include an additional agent, such as an anti-bacterial, anti-fungal, anti-viral, or anti-parasitic agent.
The patent also discloses a method of producing the bacterial composition by combining the two species of bacteria, which are capable of inhibiting C. difficile growth and/or populating the gastrointestinal tract of a subject. The method may involve lyophilizing the bacteria for stability.
Overall, this patent describes a composition and methods for using it to treat or prevent Clostridium difficile infection and dysbiosis. The composition contains two species of bacteria that inhibit C. difficile growth and can be formulated for populating the gastrointestinal tract. The patent also covers the production of the composition, as well as kits and pharmaceutical formulations containing it.
To know more about GlobalData’s detailed insights on Seres Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
